| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hui Sun, Sarah Knippenberg, Nadine Thau, Daniela Ragancokova, Sonja Körner, Dongya Huang, Reinhard Dengler, Klaus Döhler, Susanne Petr. Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cellular and molecular neurobiology. vol 33. issue 3. 2013-09-04. PMID:23271639. |
glp-1 has initially been studied as a treatment for type ii diabetes based on its function as insulin secretagogue. |
2013-09-04 |
2023-08-12 |
mouse |
| Caitriona M Long-Smith, Sean Manning, Paula L McClean, Meghan F Coakley, Domhnall J O'Halloran, Christian Holscher, Cora O'Neil. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular medicine. vol 15. issue 1. 2013-08-29. PMID:23011726. |
liraglutide, a novel glucagon-like peptide 1 (glp-1) analogue that facilitates insulin signalling, is currently approved for use in type 2 diabetes mellitus. |
2013-08-29 |
2023-08-12 |
mouse |
| Rohit Kohli, Kenneth Dr Setchell, Michelle Kirby, Andriy Myronovych, Karen K Ryan, Samar H Ibrahim, Jose Berger, Kathi Smith, Mouhamadoul Toure, Stephen C Woods, Randy J Seele. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology. vol 154. issue 7. 2013-08-28. PMID:23592746. |
glucose tolerance, insulin and glucagon-like peptide-1 (glp-1) response, hepatic steatosis, and endoplasmic reticulum (er) stress were measured. |
2013-08-28 |
2023-08-12 |
rat |
| Jia Nie, Brendan N Lilley, Y Albert Pan, Omar Faruque, Xiaolei Liu, Weiping Zhang, Joshua R Sanes, Xiao Han, Yuguang Sh. SAD-A potentiates glucose-stimulated insulin secretion as a mediator of glucagon-like peptide 1 response in pancreatic β cells. Molecular and cellular biology. vol 33. issue 13. 2013-08-27. PMID:23629625. |
type 2 diabetes is characterized by defective glucose-stimulated insulin secretion (gsis) from pancreatic β cells, which can be restored by glucagon-like peptide 1 (glp-1), an incretin hormone commonly used for the treatment of type 2 diabetes. |
2013-08-27 |
2023-08-12 |
mouse |
| Juris J Meie. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature reviews. Endocrinology. vol 8. issue 12. 2013-08-26. PMID:22945360. |
in healthy humans, the incretin glucagon-like peptide 1 (glp-1) is secreted after eating and lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon release. |
2013-08-26 |
2023-08-12 |
Not clear |
| Elin Hall, Tasnim Dayeh, Clare L Kirkpatrick, Claes B Wollheim, Marloes Dekker Nitert, Charlotte Lin. DNA methylation of the glucagon-like peptide 1 receptor (GLP1R) in human pancreatic islets. BMC medical genetics. vol 14. 2013-08-26. PMID:23879380. |
insulin secretion is enhanced upon the binding of glucagon-like peptide-1 (glp-1) to its receptor (glp1r) in pancreatic β cells. |
2013-08-26 |
2023-08-12 |
human |
| Astrid Plamboeck, Simon Veedfald, Carolyn F Deacon, Bolette Hartmann, André Wettergren, Lars B Svendsen, Søren Meisner, Claus Hovendal, Tina Vilsbøll, Filip K Knop, Jens J Hols. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. American journal of physiology. Gastrointestinal and liver physiology. vol 304. issue 12. 2013-08-23. PMID:23599045. |
insulin secretion was unaffected by exogenous glp-1 in vagotomized subjects but was suppressed in controls. |
2013-08-23 |
2023-08-12 |
human |
| Astrid Plamboeck, Simon Veedfald, Carolyn F Deacon, Bolette Hartmann, André Wettergren, Lars B Svendsen, Søren Meisner, Claus Hovendal, Tina Vilsbøll, Filip K Knop, Jens J Hols. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. American journal of physiology. Gastrointestinal and liver physiology. vol 304. issue 12. 2013-08-23. PMID:23599045. |
our results demonstrate that vagotomy with pyloroplasty impairs the effects of exogenous glp-1 on food intake, gastric emptying, and insulin and glucagon secretion, suggesting that intact vagal innervation may be important for glp-1's actions. |
2013-08-23 |
2023-08-12 |
human |
| Surabhi Venkata Satya Krishna, Sunil K Kota, Kirtikumar D Mod. Glycemic variability: Clinical implications. Indian journal of endocrinology and metabolism. vol 17. issue 4. 2013-08-20. PMID:23961476. |
modern diabetes management modalities including improved sulfonylureas, glucagon like peptide-1 (glp-1)-based therapy, newer basal insulins, and modern insulin pumps address the issue of gv effectively. |
2013-08-20 |
2023-08-12 |
Not clear |
| Alessandra Puddu, François Mach, Alessio Nencioni, Giorgio Luciano Viviani, Fabrizio Montecucc. An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediators of inflammation. vol 2013. 2013-08-19. PMID:23365488. |
glp-1 has been shown to regulate blood glucose levels by stimulating glucose-dependent insulin secretion and inhibiting glucagon secretion, gastric emptying, and food intake. |
2013-08-19 |
2023-08-12 |
Not clear |
| Alessandra Puddu, François Mach, Alessio Nencioni, Giorgio Luciano Viviani, Fabrizio Montecucc. An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediators of inflammation. vol 2013. 2013-08-19. PMID:23365488. |
these antidiabetic activities highlight glp-1 as a potential therapeutic molecule in the clinical management of type 2 diabetes, (a disease characterized by progressive decline of beta-cell function and mass, increased insulin resistance, and final hyperglycemia). |
2013-08-19 |
2023-08-12 |
Not clear |
| Angela M Abbatecola, Fabiola Olivieri, Andrea Corsonello, Felice Strollo, Alessia Fumagalli, Fabrizia Lattanzi. Frailty and safety: the example of diabetes. Drug safety. vol 35 Suppl 1. 2013-08-14. PMID:23446787. |
available oral antidiabetic drugs include insulin secretagogues (meglitinides and sulfonylureas), biguanides (metformin), α-glucosidase inhibitors, thiazolidinediones and inhibitors of glucagon-like peptide 1 (glp-1) degrading enzyme dipeptidyl peptidase 4. |
2013-08-14 |
2023-08-12 |
Not clear |
| K Gotoh, T Masaki, S Chiba, H Ando, K Fujiwara, T Shimasaki, K Mitsutomi, I Katsuragi, T Kakuma, T Sakata, H Yoshimats. Hypothalamic brain-derived neurotrophic factor regulates glucagon secretion mediated by pancreatic efferent nerves. Journal of neuroendocrinology. vol 25. issue 3. 2013-08-12. PMID:23157205. |
we investigate whether: (i) the central infusion of bdnf stimulates glucagon and/or insulin secretion via the pancreatic efferent nerve from the hypothalamus; (ii) the intraportal infusion of glp-1 regulates glucose metabolism via the central and peripheral nervous system; and (iii) bdnf receptor and/or bdnf-positive fibres are localised near α cells of islets. |
2013-08-12 |
2023-08-12 |
human |
| Aljosa Bave. Mono-ADP-ribosyltransferase as a potential pharmacological drug target in the GLP-1 based therapy of obesity and diabetes mellitus type 2. Acta chimica Slovenica. vol 60. issue 2. 2013-08-07. PMID:23878926. |
glp-1 receptor agonists should be administered in low doses, together with drugs that potentiate insulin release, to avoid some minor side effects. |
2013-08-07 |
2023-08-12 |
Not clear |
| Akiko Mizokami, Yu Yasutake, Jing Gao, Miho Matsuda, Ichiro Takahashi, Hiroshi Takeuchi, Masato Hirat. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PloS one. vol 8. issue 2. 2013-08-06. PMID:23437377. |
glucagon-like peptide-1 (glp-1) is an insulin secretagogue that is released from the gut in response to food intake. |
2013-08-06 |
2023-08-12 |
mouse |
| Akiko Mizokami, Yu Yasutake, Jing Gao, Miho Matsuda, Ichiro Takahashi, Hiroshi Takeuchi, Masato Hirat. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PloS one. vol 8. issue 2. 2013-08-06. PMID:23437377. |
serum insulin levels were also increased by ucoc, and this effect was potentiated by an inhibitor of dipeptidyl peptidase iv and blocked by a glp-1 receptor antagonist. |
2013-08-06 |
2023-08-12 |
mouse |
| Akiko Mizokami, Yu Yasutake, Jing Gao, Miho Matsuda, Ichiro Takahashi, Hiroshi Takeuchi, Masato Hirat. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PloS one. vol 8. issue 2. 2013-08-06. PMID:23437377. |
intravenous injection of ucoc in mice increased the serum glp-1 concentration, and also increased the serum level of insulin. |
2013-08-06 |
2023-08-12 |
mouse |
| Akiko Mizokami, Yu Yasutake, Jing Gao, Miho Matsuda, Ichiro Takahashi, Hiroshi Takeuchi, Masato Hirat. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PloS one. vol 8. issue 2. 2013-08-06. PMID:23437377. |
our results suggest that ucoc acts via gprc6a to induce glp-1 release from the gut, and that the stimulatory effect of ucoc on insulin secretion is largely mediated by glp-1. |
2013-08-06 |
2023-08-12 |
mouse |
| O O Ojo, J M Conlon, P R Flatt, Y H A Abdel-Waha. Frog skin peptides (tigerinin-1R, magainin-AM1, -AM2, CPF-AM1, and PGla-AM1) stimulate secretion of glucagon-like peptide 1 (GLP-1) by GLUTag cells. Biochemical and biophysical research communications. vol 431. issue 1. 2013-08-02. PMID:23291176. |
the data indicate that frog skin peptides, by stimulating glp-1 release as well as direct effects on insulin secretion, show therapeutic potential as agents for the treatment of type 2 diabetes. |
2013-08-02 |
2023-08-12 |
xenopus_laevis |
| Serge Halim. [Management of type 2 diabetes: new or previous agents, how to choose?]. Presse medicale (Paris, France : 1983). vol 42. issue 5. 2013-08-02. PMID:23643613. |
if dual oral therapy does not achieve the goals we are faced with three options: triple oral therapy: metformin-sulfonylurea-gliptine or one of two approaches with injections, insulin or glp-1 analogues. |
2013-08-02 |
2023-08-12 |
Not clear |